INSM
Insmed Incorporated · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website insmed.com
- Employees(FY) 736
- ISIN US4576693075
Performance
+3.85%
1W
+21.01%
1M
+8.15%
3M
+7.5%
6M
+15.19%
YTD
+186.08%
1Y
Profile
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis, cystic fibrosis, and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Technical Analysis of INSM 2025-02-10
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2025-02-10 19:00
- 2025-02-10 06:33
Daily – Vickers Top Buyers & Sellers for 02/10/2025(Argus Research)
- 2025-02-09 19:00
- 2025-02-07 17:23
- 2025-02-07 17:22
- 2025-02-07 17:22
- 2025-02-07 17:21
- 2025-02-07 17:21
- 2025-02-07 17:21
- 2025-02-07 17:19
- 2025-02-07 08:53
- 2025-02-06 19:00
- 2025-02-06 10:37
- 2025-02-06 08:00
- 2025-02-06 07:58
- 2025-02-05 19:00
- 2025-02-05 16:46
- 2025-01-31 16:44
- 2025-01-24 03:00
- 2025-01-21 06:36
- 2025-01-18 17:46
- 2025-01-18 04:46
- 2025-01-16 16:44
- 2025-01-15 12:29
Insmed’s gene therapy poised to challenge DMD landscape after IND clearance(Pharmaceutical Technology)
- 2025-01-13 15:06
Why INSM Stock Is Advancing Today(Insider Monkey)
- 2025-01-13 06:37
Daily – Vickers Top Buyers & Sellers for 01/13/2025(Argus Research)
- 2025-01-10 12:47
Insmed Says Full-year Revenue Expected to Rise 19%(MT Newswires)
- 2025-01-10 08:00
- 2025-01-09 19:00
- 2025-01-06 03:28
Page 1 of 10
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.